menu
    • menu
    [{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MOR202","moa":"CD38","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BION-1301","moa":"APRIL","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BION-1301","moa":"APRIL","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BION-1301","moa":"APRIL","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rockwell Medical \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BION-1301","moa":"BCMA receptor","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chinook Therapeutics \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Therapeutics \/ Evotec"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BION-1301","moa":"BCMA receptor","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Orbsen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Mesenchymal Stromal Cell","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Orbsen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orbsen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orbsen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"DISC-0974","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Povetacicept","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Povetacicept","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Alpine Immune Sciences \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Povetacicept","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Alpine Immune Sciences \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Disc medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"DISC-0974","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Disc medicine \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ARO-CFB","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Povetacicept","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":4.9000000000000004,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":4.9000000000000004,"dosageForm":"Injection","sponsorNew":"Alpine Immune Sciences \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Povetacicept","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"ARO-CFB","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARO-CFB

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arrowhead Initiates Phase 1/2a Study Of ARO-CFB for Kidney Disease Treatment

                            Details : ARO-CFB, designed to reduce hepatic complement factor B (CFB) expression, is being studied for IgA Nephropathy.

                            Brand Name : ARO-CFB

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 24, 2024

                            Lead Product(s) : ARO-CFB

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alpine Immune Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Alpine Immune Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Povetacicept

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : $4,900.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

                            Details : Through the acquisition, Vertex expands its immunology portfolio with ALPN-303 (povetacicept), a dual antagonist of BAFF and APRIL, entering late-stage trials for IgA nephropathy.

                            Brand Name : ALPN-303

                            Molecule Type : Large molecule

                            Upfront Cash : $4,900.0 million

                            April 10, 2024

                            Lead Product(s) : Povetacicept

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : $4,900.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alpine Immune Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Alpine Immune Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Povetacicept

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy

                            Details : ALPN-303 (povetacicept) is a BAFF/APRIL inhibitor, subcutaneously administered protein drug candidate, which is currently being evaluated for the treatment of IgA nephropathy.

                            Brand Name : ALPN-303

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 10, 2024

                            Lead Product(s) : Povetacicept

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARO-CFB

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complemen...

                            Details : ARO-CFB is designed to reduce hepatic expression of complement factor B. Currently, it is being evaluated in the Phase I/II clinical trial studies for the treatment of complement-mediated renal disease, such as immunoglobulin A nephropathy.

                            Brand Name : ARO-CFB

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 21, 2023

                            Lead Product(s) : ARO-CFB

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alpine Immune Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Alpine Immune Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Povetacicept

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Morgan Stanley

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Alpine Immune Sciences Announces Pricing of $150 Million Public Offering

                            Details : The net proceeds will be used to further advance the development of ALPN-303 (povetacicept) for multiple autoimmune diseases, including a potential pivotal phase 3 study in IgAN and a phase 2 study in systemic lupus erythematosus.

                            Brand Name : ALPN-303

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 06, 2023

                            Lead Product(s) : Povetacicept

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Morgan Stanley

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Alpine Immune Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Alpine Immune Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Povetacicept

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Morgan Stanley

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Alpine Immune Sciences Announces Proposed Public Offering

                            Details : The net proceeds will be used to further advance the development of ALPN-303 (povetacicept) for multiple autoimmune diseases, including a potential pivotal phase 3 study in IgAN and a phase 2 study in systemic lupus erythematosus.

                            Brand Name : ALPN-303

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 06, 2023

                            Lead Product(s) : Povetacicept

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Morgan Stanley

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Alpine Immune Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Alpine Immune Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Povetacicept

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinica...

                            Details : ALPN-303 (povetacicept) is a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, which play key roles in pathogenesis of multiple autoimmune diseases like IgA Nephropathy.

                            Brand Name : ALPN-303

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 30, 2023

                            Lead Product(s) : Povetacicept

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Disc medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Disc medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DISC-0974

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic...

                            Details : DISC-0974 is an investigational monoclonal antibody (mAb) targeting a BMP-signaling co-receptor called hemojuvelin (HJV) and is designed to suppress hepcidin production and increase serum iron levels in patients suffering from anemia of inflammation.

                            Brand Name : DISC-0974

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 16, 2023

                            Lead Product(s) : DISC-0974

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Orbsen Therapeutics

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Orbsen Therapeutics

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesenchymal Stromal Cell

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Orbsen Therapeutics Announces Encouraging Interim Results from The NEPHSTROM Proof of Concept Clinical Study E...

                            Details : ORBCEL-M is a proprietary formulation of highly purified immunomodulatory stromal cells. It is being developed for adult subjects with type 2 diabetes and progressive diabetic kidney disease (DKD).

                            Brand Name : ORBCEL-M

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 26, 2023

                            Lead Product(s) : Mesenchymal Stromal Cell

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kezar Life Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kezar Life Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zetomipzomib

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib ...

                            Details : KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.

                            Brand Name : KZR-616

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 14, 2022

                            Lead Product(s) : Zetomipzomib

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth